Jacobio Pharmaceuticals Group (JBPHF) Stock Price, News & Analysis

Company Overview

Jacobio Pharmaceuticals Group Co., Ltd. is a clinical‐stage biopharmaceutical company headquartered in Tianjin, China, specializing in the discovery and development of small‐molecule therapeutics for oncology. The company’s research platform is built around targeted kinase inhibitors and epigenetic modulators aimed at addressing acute leukemias and select solid tumors with high unmet medical need.

Jacobio’s pipeline comprises multiple preclinical and clinical‐stage programs focused on genetically defined cancers, including agents designed to inhibit mutant FLT3, menin‐MLL interactions and other oncogenic drivers. Through its internal R&D capabilities, the company advances its lead candidates from target validation through Phase I/II studies, seeking to establish proof-of-concept in both monotherapy and combination regimens.

Since its founding in 2007, Jacobio has expanded its footprint across mainland China, with research centers in Tianjin and collaborative networks involving academic institutions and contract research organizations. The company maintains in-house manufacturing capacity for early-stage compounds and pursues strategic partnerships to support late-stage development and potential global commercialization.

Key Stats

• Today's Range: $0.60 to $0.60
• 50-Day Range: $0.60 to $0.87
• 52-Week Range: $0.60 to $1.10
• Volume: N/A
• Average Volume: 300 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:JBPHF
• CIK: N/A
• Web: www.jacobiopharma.com
• Phone: 86-10-5631-5466
• Fax: N/A
• Employees: 301
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A